These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38053658)

  • 1. Novel combinatorial therapy of oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model.
    Garofalo M; Wieczorek M; Anders I; Staniszewska M; Lazniewski M; Prygiel M; Zasada AA; Szczepińska T; Plewczynski D; Salmaso S; Caliceti P; Cerullo V; Alemany R; Rinner B; Pancer K; Kuryk L
    Front Oncol; 2023; 13():1259314. PubMed ID: 38053658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Priming with oncolytic adenovirus followed by anti-PD-1 and paclitaxel treatment leads to improved anti-cancer efficacy in the 3D TNBC model.
    Kuryk L; Mathlouthi S; Wieczorek M; Gad B; Rinner B; Malfanti A; Mastrotto F; Salmaso S; Caliceti P; Garofalo M
    Eur J Pharm Biopharm; 2024 Jun; 199():114300. PubMed ID: 38697488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model.
    Garofalo M; Bertinato L; Staniszewska M; Wieczorek M; Salmaso S; Schrom S; Rinner B; Pancer KW; Kuryk L
    Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33919827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From Immunosuppression to Immunomodulation - Turning Cold Tumours into Hot.
    Garofalo M; Pancer KW; Wieczorek M; Staniszewska M; Salmaso S; Caliceti P; Kuryk L
    J Cancer; 2022; 13(9):2884-2892. PubMed ID: 35912004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model.
    Kuryk L; Møller AW; Garofalo M; Cerullo V; Pesonen S; Alemany R; Jaderberg M
    J Med Virol; 2018 Oct; 90(10):1669-1673. PubMed ID: 29797583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.
    Kuryk L; Haavisto E; Garofalo M; Capasso C; Hirvinen M; Pesonen S; Ranki T; Vassilev L; Cerullo V
    Int J Cancer; 2016 Oct; 139(8):1883-93. PubMed ID: 27287512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
    Clubb JHA; Kudling TV; Girych M; Haybout L; Pakola S; Hamdan F; Cervera-Carrascon V; Hemmes A; Grönberg-Vähä-Koskela S; Santos JM; Quixabeira DCA; Basnet S; Heiniö C; Arias V; Jirovec E; Kaptan S; Havunen R; Sorsa S; Erikat A; Schwartz J; Anttila M; Aro K; Viitala T; Vattulainen I; Cerullo V; Kanerva A; Hemminki A
    Front Immunol; 2023; 14():1060540. PubMed ID: 36817448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
    Clubb JHA; Kudling TV; Heiniö C; Basnet S; Pakola S; Cervera Carrascón V; Santos JM; Quixabeira DCA; Havunen R; Sorsa S; Zheng V; Salo T; Bäck L; Aro K; Tulokas S; Loimu V; Hemminki A
    Front Immunol; 2022; 13():794251. PubMed ID: 35355980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic adenovirus decreases the proportion of TIM-3
    Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.
    Takagi-Kimura M; Yamano T; Tamamoto A; Okamura N; Okamura H; Hashimoto-Tamaoki T; Tagawa M; Kasahara N; Kubo S
    Cancer Sci; 2013 Nov; 104(11):1433-9. PubMed ID: 23962292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
    Santos JM; Heiniö C; Cervera-Carrascon V; Quixabeira DCA; Siurala M; Havunen R; Butzow R; Zafar S; de Gruijl T; Lassus H; Kanerva A; Hemminki A
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD-1 monotherapy in colorectal cancer.
    Huang L; Zhao H; Shan M; Chen H; Xu B; He Y; Zhao Y; Liu Z; Chen J; Xu Q
    Cancer Med; 2022 Dec; 11(23):4575-4587. PubMed ID: 35762456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
    Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
    Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model.
    Zhang H; Xie W; Zhang Y; Dong X; Liu C; Yi J; Zhang S; Wen C; Zheng L; Wang H
    Cancer Gene Ther; 2022 May; 29(5):456-465. PubMed ID: 34561555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
    Tamanna MT; Egbune C
    Cancer Treat Res; 2023; 185():79-89. PubMed ID: 37306905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
    Sobhani N; Roviello G; Pivetta T; Ianza A; Bonazza D; Zanconati F; Giudici F; Bottin C; Corona SP; Guglielmi A; Rizzardi C; Milione M; Cortale M; Confalonieri M; Generali D
    Mol Biol Rep; 2019 Jun; 46(3):2713-2720. PubMed ID: 30840203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation.
    Tada A; Minami T; Kitai H; Higashiguchi Y; Tokuda M; Higashiyama T; Negi Y; Horio D; Nakajima Y; Otsuki T; Mikami K; Takahashi R; Nakamura A; Kitajima K; Ohmuraya M; Kuribayashi K; Kijima T
    Lung Cancer; 2023 Jun; 180():107219. PubMed ID: 37146474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.